Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lachmann

Showing results (31-40 of 1,793) with videos related to

Pageof 180
Sort By:
Immunology Today|September 1, 1991
The control of homologous lysisP J Lachmann
QJM : Monthly Journal of the Association of Physicians|August 22, 2012
The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticalsP J Lachmann
Current Opinion in Investigational Drugs (London, England : 2000)|June 18, 2003
Miglustat. Oxford GlycoSciences/ActelionRobin H Lachmann
Current Opinion in Pediatrics|September 28, 2011
Enzyme replacement therapy for lysosomal storage diseasesRobin H Lachmann
Current Opinion in Investigational Drugs (London, England : 2000)|November 13, 2004
alpha-glucosidase (CHO) (Genzyme)Robin H Lachmann
Journal of Immunological Methods|November 14, 2009
Preparing serum for functional complement assaysP J Lachmann
Journal of Inherited Metabolic Disease|May 30, 2019
Treating lysosomal storage disorders: What have we learnt?Robin H Lachmann
Expert Review of Endocrinology & Metabolism|February 13, 2019
Substrate-reduction therapy with miglustat for glycosphingolipid storage disorders affecting the brainRobin H Lachmann
Immunobiology|March 12, 2018
Looking back on the alternative complement pathwayPeter J Lachmann
Current Biology : CB|April 16, 1998
Microbial immunology: a new mechanism for immune subversionP J Lachmann
Pageof 180

Showing results (31-40 of 1,793) with videos related to

Sort By:
Pageof 180
Immunology Today|September 1, 1991
The control of homologous lysisP J Lachmann
QJM : Monthly Journal of the Association of Physicians|August 22, 2012
The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticalsP J Lachmann
Current Opinion in Investigational Drugs (London, England : 2000)|June 18, 2003
Miglustat. Oxford GlycoSciences/ActelionRobin H Lachmann
Current Opinion in Pediatrics|September 28, 2011
Enzyme replacement therapy for lysosomal storage diseasesRobin H Lachmann
Current Opinion in Investigational Drugs (London, England : 2000)|November 13, 2004
alpha-glucosidase (CHO) (Genzyme)Robin H Lachmann
Journal of Immunological Methods|November 14, 2009
Preparing serum for functional complement assaysP J Lachmann
Journal of Inherited Metabolic Disease|May 30, 2019
Treating lysosomal storage disorders: What have we learnt?Robin H Lachmann
Expert Review of Endocrinology & Metabolism|February 13, 2019
Substrate-reduction therapy with miglustat for glycosphingolipid storage disorders affecting the brainRobin H Lachmann
Immunobiology|March 12, 2018
Looking back on the alternative complement pathwayPeter J Lachmann
Current Biology : CB|April 16, 1998
Microbial immunology: a new mechanism for immune subversionP J Lachmann
Pageof 180